IRF3 and non-small cell lung carcinoma: In a study on non-small cell lung cancer, TANIGUCHI et al.25 demonstrated that AZD1775 could activate the stimulator of IFN genes -TBK1-IRF3 pathway, stimulating the release of pro-inflammatory chemokines CCL5 and CXCL10, as well as type I IFN.